FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma

14 Feb 2024
www.pharmaceutical-technology.com
Phase 3Clinical ResultDrug ApprovalFast Track
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma
Preview
Source: Pharmaceutical Technology
Ipsen’s Onivyde regimen is indicated as a first-line treatment for metastatic pancreatic adenocarcinoma. Credit: MattL_Images / Shutterstock.com.
The US Food and Drug Administration approved Ipsen‘s supplemental new drug application for the Onivyde (irinotecan liposome injection) combination regimen (NALIRIFOX) as a first-line treatment for metastatic pancreatic adenocarcinoma (mPDAC) in adults.
The treatment is indicated for use with oxaliplatin, fluorouracil and leucovorin.
It is the second FDA approval for an Onivyde regimen in mPDAC, expanding treatment options for patients.
In 2015, the regulator approved Onivyde plus fluorouracil and leucovorin in patients experiencing disease progression following gemcitabine-based therapy.
The latest approval is based on findings from the Phase III NAPOLI 3 clinical trial.
See Also:FDA grants fast track status to Edgewise’s Duchenne treatment
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma
Preview
Source: Pharmaceutical Technology
SCOPE: FDA facilitates AI and ML use for clinical trials and drug development
FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma
Preview
Source: Pharmaceutical Technology
The open-label, randomised trial enrolled 770 individuals across 187 sites in 18 countries.
The trial met its primary and secondary endpoints, showing improvements in survival rates for subjects treated with the Onivyde regimen compared to those receiving nab-paclitaxel and gemcitabine.
Patients treated with the Onivyde regimen, NALIRIFOX, experienced a median overall survival of 11.1 months, notably longer than the 9.2 months observed in patients treated with nab-paclitaxel and gemcitabine.
The Onivyde combination also led to a median progression-free survival of 7.4 months, compared to 5.6 months under the alternative treatment.
The objective response rate for the NALIRIFOX regimen was 41.8%, against the 36.2% rate for those receiving nab-paclitaxel and gemcitabine.
Despite the potential for serious adverse events such as fatal neutropenic fever and severe diarrhoea, the safety profile of the Onivyde regimen was deemed manageable.
Ipsen Research and Development EVP and head Christelle Huguet stated: “With today’s approval, this Onivyde (NALIRIFOX) regimen can now offer a potential new standard-of-care treatment option with proven survival benefits for people living with metastatic pancreatic adenocarcinoma in the US.”
Ipsen holds sole rights to market Onivyde in the US for existing and future indications while Servier will commercialise the therapy outside the US and Taiwan.
In August 2023, Ipsen received FDA approval for Sohonos (palovarotene) capsules to treat fibrodysplasia ossificans progressiva.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.